United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate tablets are contraindicated in patients: - with urinary retention [see warnings and precautions (5.2)] , - with gastric retention [see warnings and precautions (5.3)] , - with uncontrolled narrow-angle glaucoma [see warnings and precautions (5.5)] , and - who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. reported adverse reactions have included anaphylaxis and angioedema [see

United States - English - NLM (National Library of Medicine)

proficient rx lp - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate tablets are contraindicated in patients: risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the period of organogenesis at a dose resulting in 1.2 times the systemic exposure at the maximum recommended human dose (mrhd) of 10 mg/day. however, administration of doses 3.6 times and greater than the mrhd during organogenesis produced maternal toxicity in the pregnant mice and resulted in developmental toxicity and reduced fetal body weights in offspring [see data] . in the u.s. general population, the estimated

United States - English - NLM (National Library of Medicine)

proficient rx lp - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate tablets are contraindicated in patients: risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes. no adverse developmental outcomes were observed in animal reproduction studies with oral administration of solifenacin succinate to pregnant mice during the period of organogenesis at a dose resulting in 1.2 times the systemic exposure at the maximum recommended human dose (mrhd) of 10 mg/day. however, administration of doses 3.6 times and greater than the mrhd during organogenesis produced maternal toxicity in the pregnant mice and resulted in developmental toxicity and reduced fetal body weights in offspring [see data] . in the u.s. general population, the estimated

United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - solifenacin succinate (unii: kka5dld701) (solifenacin - unii:a8910sqj1u) - solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. solifenacin succinate tablets are contraindicated in patients: • with urinary retention [see warnings and precautions ( 5.2)], • with gastric retention [see warnings and precautions ( 5.3)], • with uncontrolled narrow-angle glaucoma [see warnings and precautions ( 5.5)], and • who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in solifenacin succinate tablets. reported adverse reactions have included anaphylaxis and angioedema [see adverse reactions ( 6.2)]. risk summary there are no studies with the use of solifenacin succinate in pregnant women to inform a drug-associated risk of major birth defects, mis

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - solifenacin succinate, quantity: 5 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; purified water; hypromellose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - solifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - solifenacin succinate, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; lactose monohydrate; purified water; maize starch; magnesium stearate; titanium dioxide; macrogol 8000; purified talc; iron oxide red - solifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - solifenacin succinate, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified water; maize starch; hypromellose; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - solifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - solifenacin succinate, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; lactose monohydrate; purified water; maize starch; magnesium stearate; titanium dioxide; macrogol 8000; purified talc; iron oxide red - solifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency or increased urinary frequency.

Malta - English - Medicines Authority

teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - solifenacin succinate - film-coated tablet - solifenacin succinate 5 mg - urologicals

Malta - English - Medicines Authority

teva pharma b.v. (utrecht) swensweg 5, 2031 ga haarlem, netherlands - solifenacin succinate - film-coated tablet - solifenacin succinate 10 mg - urologicals